Evidence map›Paper›PMID 36891316›Full record

ArticleFrontiers in immunology2023

Evaluating SARS-CoV-2 antibody reactivity to natural exposure and inactivated vaccination with peptide microarrays.

Peiyan Zheng, Jing Ma, Jiao Yang, Baolin Liao, Zhangkai J Cheng, Mingshan Xue, Shiyun Li, Yanting Fang, Runpei Lin, Guizhen Zhang and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Peiyan ZhengDepartment of Allergy and Clinical Immunology, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Laboratory, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Jing MaDepartment of Allergy and Clinical Immunology, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Laboratory, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Jiao YangDivision of Nanobiomedicine, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou, China.
Baolin LiaoGuangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
Zhangkai J ChengDepartment of Allergy and Clinical Immunology, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Laboratory, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Mingshan XueDepartment of Allergy and Clinical Immunology, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Laboratory, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Shiyun LiDepartment of Allergy and Clinical Immunology, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Laboratory, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Yanting FangDepartment of Allergy and Clinical Immunology, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Laboratory, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Runpei LinDepartment of Allergy and Clinical Immunology, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Laboratory, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Guizhen ZhangDepartment of Allergy and Clinical Immunology, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Laboratory, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Huimin HuangDepartment of Allergy and Clinical Immunology, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Laboratory, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Fengyu HuGuangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
Hongwei MaDivision of Nanobiomedicine, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou, China.
Baoqing SunDepartment of Allergy and Clinical Immunology, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Laboratory, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
First Affiliated Hospital of Guangzhou Medical University · CNChinese Academy of Sciences · CNGuangzhou Eighth People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Vaccination is effective tool for preventing and controlling SARS-CoV-2 infections, and inactivated vaccines are the most widely used type of vaccine. In order to identify antibody-binding peptide epitopes that can distinguish between individuals who have been vaccinated and those who have been infected, this study aimed to compare the immune responses of vaccinated and infected individuals. Methods: SARS-CoV-2 peptide microarrays were used to assess the differences between 44 volunteers inoculated with the inactivated virus vaccine BBIBP-CorV and 61 patients who were infected with SARS-CoV-2. Clustered heatmaps were used to identify differences between the two groups in antibody responses to peptides such as M1, N24, S15, S64, S82, S104, and S115. Receiver operating characteristic curve analysis was used to determine whether a combined diagnosis with S15, S64, and S104 could effectively distinguish infected patients from vaccinated individuals. Results: Our findings showed that the specific antibody responses against S15, S64, and S104 peptides were stronger in vaccinators than in infected persons, while responses to M1, N24, S82, and S115 were weaker in asymptomatic patients than in symptomatic patients. Additionally, two peptides (N24 and S115) were found to correlate with the levels of neutralizing antibodies. Conclusion: Our results suggest that antibody profiles specific to SARS-CoV-2 can be used to distinguish between vaccinated individuals and those who are infected. The combined diagnosis with S15, S64, and S104 was found to be more effective in distinguishing infected patients from those who have been vaccinated than the diagnosis using individual peptides. Moreover, the specific antibody responses against the N24 and S115 peptides were found to be consistent with the changing trend of neutralizing antibodies.

Indexed as

COVID-19SARS-CoV-2Antibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesHumansPeptidesVaccinationVaccines, InactivatedAntibodies, NeutralizingAntibodies, ViralBIBP COVID-19 vaccineCOVID-19 VaccinesPeptidesVaccines, Inactivatedantibody responseasymptomatic infectionspeptide microarraysSARS-CoV-2vaccination

Identifiers

PMID36891316
PMCPMC9986310
OpenAlexW4321376741

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.